2021 Fiscal Year Final Research Report
Development of combination immunotherapy with peptide vaccines for renal cell carcinoma.
| Project/Area Number |
19H03794
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56030:Urology-related
|
|---|
| Research Institution | Kindai University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
デベラスコ マルコ 近畿大学, 医学部, 講師 (20449838)
原田 守 島根大学, 学術研究院医学・看護学系, 教授 (50260716)
南 高文 近畿大学, 医学部, 講師 (70340809)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 腎細胞癌 / ペプチドワクチン / 複合免疫療法 / バイオマーカー |
|---|
| Outline of Final Research Achievements |
We have been working on the development of new MHC Class-I restricted peptide vaccines for five independent therapeutic targets (CA9, VEGFR1, EPOR, PDL1, HIF1) and our studies have successfully resulted in two Japanese patents (#6900610, #6918333) in 2021. We are currently investigating immunological evaluations of our peptide vaccines with immune check point therapies using PBMCs from advanced RCC patients receiving IO-drugs. Most of the data such as ability of specific CTL induction are not reported in public due to patent.
|
| Free Research Field |
泌尿器腫瘍学
|
| Academic Significance and Societal Importance of the Research Achievements |
昨今、免疫チェックポイント阻害薬（IO-drug）の登場により、がん免疫療法の有用性が再認識されている。近い将来、癌治療は抗がん剤や分子標的薬を用いた単一療法から、IO-drugを併用する複合免疫療法の時代へと移行してきた。このような現状を鑑みると本研究のような新規ワクチン療法とIO-drugによる複合免疫療法の有用性を検討することは重要な課題と思われる。
|
